Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
about
An Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNAAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoOptimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA.Targeting survivin in cancer: novel drug development approaches.MicroRNA regulation and therapeutic targeting of survivin in cancer.Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines.Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.Targeting survivin using a combination of miR‑494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growthMicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities.Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cellsEndogenous knockdown of survivin improves chemotherapeutic response in ALL models.Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale.Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.Hypoxic tumor microenvironment in advanced retinoblastoma.Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.Locked Nucleic Acid Oligonucleotides toward Clinical Applications
P2860
Q27664845-F99C5732-D99F-47A6-8736-2EDBB0D535DCQ30275229-4FB7DF4C-CF70-482E-9BAD-3E334008F8ACQ34547528-5E59FDED-CDEA-40F4-BC19-4C49FE514EC9Q34559630-16807434-8FB7-4C6A-B9E8-30EEA7DD2434Q34954296-739445CF-60BF-4DE8-8846-2F1BBA2C4190Q34991312-F7B19AC0-C16E-461A-92CA-38A8B6355B95Q35048722-3EE3EAA9-B912-422E-936D-9F23F641B626Q35182716-445953A3-6576-4BF8-93CE-FB5203DB59D5Q36520194-7D0827C8-BA10-45F6-8FFA-57D9E3084B87Q36691758-97E5B88A-8361-42F7-A3E0-FAAD0C8D6EE1Q36717205-1C17CA81-9388-47E7-8310-443D1200393BQ37324196-35EDCB8F-97D8-40D3-9869-855EBCA05A88Q37654710-7B660334-875F-4B40-B34D-D70A7BB1010BQ37789741-1BD83C4A-0624-44E3-9FB7-9676EA964009Q37873745-42284341-7664-48D5-81D8-F86DF97F7B51Q38212609-03AB6713-3F70-4550-A65A-6A98D12D4A98Q38395896-82B26BE7-6852-4DF2-B53B-4CE90E141702Q38985503-281AF049-A31F-4566-A60F-8F18EFFD6188Q59004652-101BEC93-F2BF-4789-B0C5-783025EF3079
P2860
Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@en
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@nl
type
label
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@en
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@nl
prefLabel
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@en
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@nl
P2093
P2860
P1476
Down-modulation of survivin ex ...... cid antisense oligonucleotide.
@en
P2093
Ivan D Horak
Lee M Greenberger
Maoliang Wang
Puja Sapra
Raj Bandaru
P2860
P304
P356
10.1080/15257771003597733
P577
2010-02-01T00:00:00Z